Non-muscle Invasive Bladder Cancer (NMIBC)
Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
ImmunityBioN-803 and BCG
Asieris PharmaceuticalsAPL-1202
Clinical Trials (2)
Total enrollment: 20 patients across 2 trials
Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer
Start: Nov 2025Est. completion: Nov 202920 patients
Phase 2Not Yet Recruiting
Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment
Start: Nov 2018Est. completion: Jun 2020
Phase 1/2Completed
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
1h ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
1h ago
Office Administrator
SystImmune
1h ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
1h ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
1h ago
Working Student Active Sourcing Support (m/f/d)
Mindpeak
Hamburg
1h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space